✦ LIBER ✦

Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines

✍ Scribed by Abid R. Mattoo; David J. Fitzgerald

Book ID: 115556512
Publisher: John Wiley and Sons
Year: 2012
Tongue: French
Weight: 637 KB
Volume: 132
Category: Article
ISSN: 0020-7136
DOI: 10.1002/ijc.27732

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination treatment with ABT-737 and c

Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer

✍ Rebekah L Zinn, Eric E Gardner, Irina Dobromilskaya, Sara Murphy… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 1003 KB

Phase II Study of Single-Agent Navitocla

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

✍ Rudin, C. M.; Hann, C. L.; Garon, E. B.; Ribeiro de Oliveira, M.; Bonomi, P. D.; 📂 Article 📅 2012 🏛 American Association for Cancer Research 🌐 English ⚖ 314 KB

Phase I Study of Navitoclax (ABT-263), a

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

✍ Gandhi, L.; Camidge, D. R.; Ribeiro de Oliveira, M.; Bonomi, P.; Gandara, D.; Kh 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 299 KB

Phase I Study of Navitoclax (ABT-263), a

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

✍ Gandhi, L.; Camidge, D. R.; Ribeiro de Oliveira, M.; Bonomi, P.; Gandara, D.; Kh 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 299 KB

## Purpose Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting Bcl-2 may provide therapeutic benefit. A phase I study of navitoclax, a novel inhibitor of Bcl-2 family proteins, was conduct